Enhanced Delivery of Boronophenylalanine for Neutron Capture Therapy of Brain Tumors Using the Bradykinin Analog Cereport (Receptor-Mediated Permeabilizer-7)

Enhanced Delivery of Boronophenylalanine for Neutron Capture Therapy of Brain Tumors Using the... AbstractOBJECTIVE:Using the well-characterized F98 rat glioma model, the purpose of the present study was to determine whether the delivery of boronophenylalanine (BPA) could be enhanced by prior administration of the bradykinin analog Cereport (Alkermes, Inc., Cambridge, MA) (previously known as Receptor-Mediated Permeabilizer-7), which produces a transient, pharmacologically mediated opening of the blood-brain barrier.METHODS:Two series of experiments were performed in F98 glioma-bearing rats that had received either intracarotid (i.e.) or intravenous infusions of Cereport (at doses ranging from 1.5 to 7.5 ftg/kg of body weight), followed by i.e. (or intravenous) injection of BPA (300 mg/kg of body weight). Animals were killed 0.5, 2.5, or 4 hours later, samples of blood, skin, muscle, and eye were obtained, brains were removed, and tumors were excised for boron determination by direct current plasma-atomic emission spectroscopy.RESULTS:Averaged over all time points, i.e. infusion of Cereport significantly enhanced tumor boron uptake (P = 0.0001), compared with the excipient (saline) control values. Tumor boron values were equivalent at 0.5 (36.0 g/g) and 2.5 hours (38.5/u.g/g) after i.e. administration of Cereport and BPA and then decreased by 33% (to 25.7/ug/g) at 4 hours. These tumor boron uptake values were significantly different (a = 0.05), compared with values measured at the corresponding times after i.e. administration of BPA without Cereport (22.6, 21.8, and 15.3 fxg/g, respectively). Although no time-related effects were observed, i.e. administration of Cereport followed by intravenous administrationof BPA also significantly enhanced (a = 0.05) tumor boron uptake at 0.5, 2.5, and 4 hours (27.4, 30.3, and 28-0/x.g/g, respectively), compared with values obtained without Cereport (11.3, 13.4, and 15.2 ng/g, respectively). Boron levels in normal brain tissue from tumor-bearing and non-tumor-bearing cerebral hemispheres and in blood were not significantly different from those measured in saline-treated control animals.CONCLUSION:This study established that i.e. infusion of Cereport significantly increased delivery of BPA to F98 rat gliomas, and this could enhance the efficacy of boron neutron capture therapy of this tumor. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Enhanced Delivery of Boronophenylalanine for Neutron Capture Therapy of Brain Tumors Using the Bradykinin Analog Cereport (Receptor-Mediated Permeabilizer-7)

Enhanced Delivery of Boronophenylalanine for Neutron Capture Therapy of Brain Tumors Using the Bradykinin Analog Cereport (Receptor-Mediated Permeabilizer-7)

Enhanced Delivery of Boronophenylalanine for Neutron Capture Therapy of Brain Tumors Using the Bradykinin Analog Cereport (Receptor-Mediated Permeabilizer-7) Rolf F. Barth, M .D ., Weilian Yang, M .D ., Raymond T. Bartus, Ph.D., Melvin L. Moeschberger, Ph.D., joseph H. Goodman, M.D. Departm ent of Pathology (R FB , W Y ), D ivision of Epidemiology and Biometrics (M LM ), School of Public Health, D ivision of Neurosurgery (JH C ), and the C o m p reh e n sive C a n c e r Center (R FB , W Y , M LM , ] H G ), The O h io State U niversity, C o lu m b u s, O h io , and Alkerm es, Inc. (RTB), Cambridge, Massachusetts OBJECTIVE: Using the well-characterized F98 rat glioma model, the purpose of the present study was to determine whether the delivery of boronophenylalanine (B P A ) could be enhanced by prior administration of the bradykinin analog Cereport (Alkerm es, Inc., Cambridge, M A ) (previously known as Receptor-Mediated Permeabilizer-7), which produces a transient, pharm acologically mediated opening of the blood-brain barrier. METHODS: Two series of experiments w ere performed in F98 glioma-bearing rats that had received either intracarotid (i.e.) or intravenous infusions of Cereport (at doses ranging from 1.5 to 7.5 ftg/kg of body weight), followed by i.e. (or intravenous) injection of BPA (300 mg/kg of body weight). Animals were killed 0.5, 2.5, or 4 hours later, samples of blood, skin, muscle, and eye were obtained, brains were removed, and tumors were excised for boron determ ination by direct current plasma-atomic emission spectroscopy. RESULTS: Averaged over all time points, i.e. infusion of Cereport significantly enhanced tumor boron uptake (P = 0.0001), compared with the excipient (saline) control values. Tumor boron values were equivalent at 0.5 (36.0 g/g) and 2.5 hours (38.5 /u.g/g) after i.e. adm inistration of Cereport and BPA and then decreased by 3 3 % (to 25.7 /ug/g) at 4 hours. These tumor boron uptake values were significantly different (a =...
Loading next page...
 
/lp/ou_press/enhanced-delivery-of-boronophenylalanine-for-neutron-capture-therapy-07wofz8OW0
Publisher
Congress of Neurological Surgeons
Copyright
© Published by Oxford University Press.
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1097/00006123-199902000-00062
Publisher site
See Article on Publisher Site

Abstract

AbstractOBJECTIVE:Using the well-characterized F98 rat glioma model, the purpose of the present study was to determine whether the delivery of boronophenylalanine (BPA) could be enhanced by prior administration of the bradykinin analog Cereport (Alkermes, Inc., Cambridge, MA) (previously known as Receptor-Mediated Permeabilizer-7), which produces a transient, pharmacologically mediated opening of the blood-brain barrier.METHODS:Two series of experiments were performed in F98 glioma-bearing rats that had received either intracarotid (i.e.) or intravenous infusions of Cereport (at doses ranging from 1.5 to 7.5 ftg/kg of body weight), followed by i.e. (or intravenous) injection of BPA (300 mg/kg of body weight). Animals were killed 0.5, 2.5, or 4 hours later, samples of blood, skin, muscle, and eye were obtained, brains were removed, and tumors were excised for boron determination by direct current plasma-atomic emission spectroscopy.RESULTS:Averaged over all time points, i.e. infusion of Cereport significantly enhanced tumor boron uptake (P = 0.0001), compared with the excipient (saline) control values. Tumor boron values were equivalent at 0.5 (36.0 g/g) and 2.5 hours (38.5/u.g/g) after i.e. administration of Cereport and BPA and then decreased by 33% (to 25.7/ug/g) at 4 hours. These tumor boron uptake values were significantly different (a = 0.05), compared with values measured at the corresponding times after i.e. administration of BPA without Cereport (22.6, 21.8, and 15.3 fxg/g, respectively). Although no time-related effects were observed, i.e. administration of Cereport followed by intravenous administrationof BPA also significantly enhanced (a = 0.05) tumor boron uptake at 0.5, 2.5, and 4 hours (27.4, 30.3, and 28-0/x.g/g, respectively), compared with values obtained without Cereport (11.3, 13.4, and 15.2 ng/g, respectively). Boron levels in normal brain tissue from tumor-bearing and non-tumor-bearing cerebral hemispheres and in blood were not significantly different from those measured in saline-treated control animals.CONCLUSION:This study established that i.e. infusion of Cereport significantly increased delivery of BPA to F98 rat gliomas, and this could enhance the efficacy of boron neutron capture therapy of this tumor.

Journal

NeurosurgeryOxford University Press

Published: Feb 1, 1999

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off